Quick Answer
ImageneBio, Inc. reported Total Assets of $152.98 million for the year ending 2025.
- ImageneBio, Inc. showed an increase of +860.8% in Total Assets from 2024 to 2025.
- This data is from ImageneBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $293.66 million | Q2 2021: $278.83 million | Q3 2021: $261.71 million | Q1 2022: $227.75 million | Q2 2022: $211.18 million | Q3 2022: $190.47 million | Q1 2023: $152.40 million | Q2 2023: $171.76 million | Q3 2023: $215.34 million | Q1 2024: $172.78 million | Q2 2024: $157.49 million | Q3 2024: $148.99 million | Q1 2025: $130.84 million | Q2 2025: $126.17 million | Q3 2025: $160.88 million.
- Over the full 6 years of available data (2020 to 2025), ImageneBio, Inc.'s Total Assets has declined by 9.2%.
- Historical annual values: Fiscal year 2025: $152.98 million | Fiscal year 2024: $15.92 million | Fiscal year 2023: $192.09 million | Fiscal year 2022: $172.26 million | Fiscal year 2021: $247.88 million | Fiscal year 2020: $168.40 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: